A federal false claims lawsuit alleging that Israeli pharmaceutical company Sanofi-Aventis falsely marketed its cancer drug Taxotere and provided doctors with illegal kickbacks for prescribing the drug for off-label uses can proceed.
U.S. District Judge Lawrence F. Stengel of the Eastern District of Pennsylvania denied Aventis’ request to have the case tossed on statute of limitations and First Amendment grounds, specifically that the company’s marketing statements are protected free speech.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
